Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Solid Tumors That Overexpress HER2 (HER2 Positive) × Immunoglobulin G × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Virus Diseases 1 Uterine Neoplasms 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors That Overexpress HER2 (HER2 Positive) 1 Prostatic Neoplasms 1 Liver Cirrhosis 1 Hepatitis, Viral, Human 1 Hepatitis C 1 Esophageal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1

Interventions

Immunoglobulin G 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02286219 2017-09-18

Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)

Bristol-Myers Squibb

Phase 1 Completed

Other solid neoplasm

Solid Tumors That Overexpress HER2 (HER2 Positive)

Data powered by HemOnc (CC BY 4.0) Colophon ⚡